▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Peter Stephens

TMFstockpicker

Peter is a Healthcare Specialist at The Motley Fool.

Recent Articles by Peter Stephens

Apr 25, 2014 by Peter Stephens

This Is Dividend Stock Johnson & Johnson’s Major Weakness

Although diversification can sometimes be a strength, it can also prove to be a double-edged sword in the long run. Here’s how.

Apr 17, 2014 by Peter Stephens

Johnson & Johnson's 3 Major Strengths

What are the three key reasons why J&J could be a top performer in the future?

Apr 7, 2014 by Peter Stephens

Can J&J's Pharma Segment Deliver Meaningful Growth?

In the final part of a three-part series, I take a deep dive into J&J's pharmaceuticals segment and ask whether it's as attractive as many investors believe.

Mar 28, 2014 by Peter Stephens

Don't Underestimate J&J's Best-Known Products

In the second of a three-part series I take a closer look at J&J's (NYSE: JNJ) consumer segment to find out if it could make the stock take off.

Mar 25, 2014 by Peter Stephens

Is J&J's Forgotten Half About to Take Off?

In the first of a three-part series, I put Johnson & Johnson's medical devices and diagnostics segment under the investment microscope.

Mar 20, 2014 by Peter Stephens

Why Philip Morris Could Be a Winning Stock

Philip Morris could be a strong performer in future. Here's why.

Mar 20, 2014 by Peter Stephens

Is Novartis' Strategy a Winning One?

Novartis has changed to a new strategy. Is it likely to be a successful one?

Mar 19, 2014 by Peter Stephens

Is Procter & Gamble a Buy at Current Levels?

With shares disappointing in recent years, is Procter & Gamble now attractive?

Mar 19, 2014 by Peter Stephens

Better Buy: GlaxoSmithKline, AbbVie, or Merck?

Shares in GlaxoSmithKline have underperformed the index in recent years. Does this mean the stock is undervalued?

Mar 18, 2014 by Peter Stephens

Does Bristol-Myers Squibb Offer Good Value?

Having had a strong performance in recent years, does Bristol-Myers Squibb still offer good value for your money at current price levels?

Mar 17, 2014 by Peter Stephens

Can Pfizer Outperform in 2014?

After tracking the index for five years, Pfizer could be worth buying. Here's why.

Mar 14, 2014 by Peter Stephens

Can AbbVie Continue Its Bull Run?

After an impressive share price performance since it listed, is AbbVie still worth buying?

Mar 14, 2014 by Peter Stephens

Better Buy: Johnson & Johnson, Pfizer, or Bristol-Myers Squibb?

Is the relative stability provided by Johnson & Johnson's diversified business model a major advantage when compared to Pfizer and Bristol-Myers Squibb?

Mar 13, 2014 by Peter Stephens

Can Eli Lilly Continue its Bull Run?

Despite some disappointing news, Eli Lilly's stock has made a strong start to 2014. Can it keep going?

Mar 12, 2014 by Peter Stephens

Bristol-Myers Squibb: More Than Just a Relief Rally?

Shares in Bristol-Myers Squibb performed relatively positively last week. Can they keep it going?

Mar 11, 2014 by Peter Stephens

Is Merck a Buy at Current Price Levels?

After a strong recent run, are shares in Merck (NYSE: MRK) still worth buying?

Mar 10, 2014 by Peter Stephens

Can Merck Keep Its Bull Run Going?

Shares in Merck have made a strong start to 2014. Can they keep going?

Mar 9, 2014 by Peter Stephens

Has Celgene Corporation Run Out of Steam in 2014?

After an awesome 2013, Celgene (NASDAQ: CELG) has made a bad start to the year. Can it recover?

Mar 7, 2014 by Peter Stephens

Can Bristol-Myers Squibb Keep Its Bull Run Going in 2014?

The year 2013 was a great one for Bristol-Myers Squibb (NYSE: BMY); 2014 could also be a strong year due to a potential catalyst.

Mar 6, 2014 by Peter Stephens

Can Roche Keep Its Bull Run Going?

Despite mixed recent news flow, Roche remains a company with significant potential.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services